Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2
- 1 June 1997
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (7) , 1050-1054
- https://doi.org/10.1016/s0959-8049(96)00530-8
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.Journal of Clinical Oncology, 1995
- Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2Published by American Medical Association (AMA) ,1994
- Interleukin-10 production during septicaemiaThe Lancet, 1994
- Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: Improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2European Journal Of Cancer, 1994
- Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinomaEuropean Journal Of Cancer, 1993
- Human interleukin-10 can directly inhibit T-cell growthBlood, 1993
- Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.Journal of Clinical Oncology, 1992
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987